Susan Galbraith

EVP, Oncology R&D · AstraZeneca

Pharmaceuticals

Susan Galbraith leads oncology research and development at AstraZeneca. A clinical oncologist by training, she built an early-development leadership career before taking responsibility for the oncology portfolio from discovery through late-stage development.

Last reviewed: Nov 16, 2026

Executive Summary

Susan Galbraith leads oncology research and development at AstraZeneca. A clinical oncologist by training, she built an early-development leadership career before taking responsibility for the oncology portfolio from discovery through late-stage development.

Career Highlights

  • Moved from early-stage oncology leadership into the group R&D role in 2021.
  • Oversaw programs including Lynparza, Tagrisso, Orpathys and Koselugo before that appointment.
  • Served on the AACR board from 2021 to 2024.

Professional Journey

Galbraith studied medicine at Manchester and Cambridge and trained in clinical oncology in London. She was admitted to the Royal College of Physicians in 1992 and completed a University of London Ph.D. in 1997, involving translational research on a vascular-targeting molecule.

She worked at Bristol-Myers Squibb before joining AstraZeneca in 2010. As senior vice president and head of Research and Early Development in Oncology, she oversaw the progression of seven programs into Phase III trials.

Medicines approved during her early-development leadership included Lynparza, Tagrisso, Orpathys and Koselugo. In 2021 she moved into leadership of Oncology R&D from discovery through late-stage development and joined the Senior Executive Team.

Her professional recognition includes Fellowship of the Academy of Medical Sciences and election to the AACR Academy. She served on AACR’s board from 2021 to 2024 and has held scientific advisory roles with the Institute of Cancer Research and the European Association for Cancer Research.

Education

Ph.D. — University of London.

University of Cambridge — Medicine.

University of Manchester — Medicine.